Longduoduo Company Limited
Longduoduo Company Limited, together its subsidiaries, provides preventive healthcare solutions in the People's Republic of China. The company offers range of preventive healthcare services, including disease screening, healthcare treatments, healthcare products, and other services for the prevention of myocardial infarction, cerebral infarction, hemiplegia, and cardiovascular and cerebrovascular… Read more
Longduoduo Company Limited (LDDD) - Net Assets
Latest net assets as of September 2025: $1.20 Million USD
Based on the latest financial reports, Longduoduo Company Limited (LDDD) has net assets worth $1.20 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($1.90 Million) and total liabilities ($700.55K). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $1.20 Million |
| % of Total Assets | 63.11% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Longduoduo Company Limited - Net Assets Trend (2021–2025)
This chart illustrates how Longduoduo Company Limited's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Longduoduo Company Limited (2021–2025)
The table below shows the annual net assets of Longduoduo Company Limited from 2021 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-06-30 | $1.30 Million | +65.98% |
| 2024-06-30 | $780.85K | +236.83% |
| 2023-06-30 | $-570.65K | +44.18% |
| 2022-06-30 | $-1.02 Million | -165.51% |
| 2021-06-30 | $-385.05K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Longduoduo Company Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 584057100.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (June 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $30.02K | 2.53% |
| Other Comprehensive Income | $77.03K | 6.50% |
| Other Components | $7.25 Million | 611.76% |
| Total Equity | $1.18 Million | 100.00% |
Longduoduo Company Limited Competitors by Market Cap
The table below lists competitors of Longduoduo Company Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
ONDO INSURTECH LS -05
F:1AI
|
$17.81 Million |
|
Pureprofile Ltd
AU:PPL
|
$17.82 Million |
|
Delticom AG
F:DEX
|
$17.82 Million |
|
SEKER YATIRIM
IS:SKYMD
|
$17.82 Million |
|
GLOSTER LTD (BSE)
NSE:GLOSTERLTD
|
$17.80 Million |
|
Yura Tech. Co. Ltd
KQ:048430
|
$17.80 Million |
|
Munjal Showa Limited
NSE:MUNJALSHOW
|
$17.80 Million |
|
Thanapiriya Public Company Limited
BK:TNP
|
$17.80 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Longduoduo Company Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 702,515 to 1,184,565, a change of 482,050 (68.6%).
- Net income of 460,435 contributed positively to equity growth.
- Other comprehensive income increased equity by 21,615.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $460.44K | +38.87% |
| Other Comprehensive Income | $21.61K | +1.82% |
| Total Change | $- | 68.62% |
Book Value vs Market Value Analysis
This analysis compares Longduoduo Company Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 124.39x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-06-30 | $0.00 | $4.91 | x |
| 2022-06-30 | $-0.03 | $4.91 | x |
| 2023-06-30 | $-0.02 | $4.91 | x |
| 2024-06-30 | $0.02 | $4.91 | x |
| 2025-06-30 | $0.04 | $4.91 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Longduoduo Company Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 38.87%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 10.80%
- • Asset Turnover: 2.00x
- • Equity Multiplier: 1.80x
- Recent ROE (38.87%) is below the historical average (43.52%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | 0.00% | -79.40% | 0.81x | 0.00x | $-295.21K |
| 2022 | 0.00% | -232.16% | 5.30x | 0.00x | $-7.42 Million |
| 2023 | 0.00% | -1.02% | 2.58x | 0.00x | $15.11K |
| 2024 | 178.71% | 16.99% | 3.58x | 2.94x | $1.19 Million |
| 2025 | 38.87% | 10.80% | 2.00x | 1.80x | $341.98K |
Industry Comparison
This section compares Longduoduo Company Limited's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $914,015,556
- Average return on equity (ROE) among peers: -22.24%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Longduoduo Company Limited (LDDD) | $1.20 Million | 0.00% | 0.58x | $17.81 Million |
| Agilent Technologies Inc (A) | $4.08 Billion | 3.46% | 0.65x | $31.80 Billion |
| Amer Bio Medica (ABMC) | $3.38 Million | -26.64% | 1.08x | $3.55K |
| ADCNF (ADCNF) | $1.77 Billion | 2.65% | 1.64x | $172.01 Million |
| Advanced Biomed Inc. Common Stock (ADVB) | $3.48 Billion | 0.00% | 0.87x | $1.68 Million |
| ANGLE plc (ANPCF) | $18.44 Million | -77.14% | 0.38x | $34.42 Million |
| SeqLL Inc. (ATLN) | $8.18 Million | -45.26% | 0.31x | $35.63K |
| Avricore Health Inc (AVCRF) | $2.20 Million | -79.50% | 0.04x | $3.22 Million |
| Aspira Womens Health Inc (AWH) | $-11.46 Million | 0.00% | 0.00x | $664.47K |
| Biodesix Inc (BDSX) | $-198.03 Million | 0.00% | 0.00x | $50.38 Million |
| bioAffinity Technologies, Inc. (BIAF) | $-15.79 Million | 0.00% | 0.00x | $5.08 Million |